Company / Accounts Receivable
Quest Diagnostics Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$1.4B
FY2025
5-year range
$1.2B / $1.4B
FY2021-FY2025
Trend
+8.0%
vs FY2024
Sector context
#20 of 138
Health Care
What the data says
Quest Diagnostics's accounts receivable of $1.4B is higher than 86% of companies in the Health Care sector (FY2025). Accounts Receivable has increased for 3 consecutive years, from $1.2B in FY2022 to $1.4B in FY2025.
Based on SEC 10-K filings.
$1.4B in FY2025 with a 5-year CAGR of -1.5%. Top quartile in the Health Care sector.
Improved from $1.2B to $1.4B over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +5.6%
- 5-Year CAGR
- -1.5%
- 10-Year CAGR
- -
Sector benchmark
+6.6% above sector average
Key checks
Key Insights
- Quest Diagnostics's accounts receivable has grown for 3 consecutive years.
- 5-year CAGR of -1.5%, indicating a declining trend.
- In FY2025, accounts receivable increased 8.0% year-over-year.
- Ranks #20 out of 138 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.4B | +8.0% |
| FY2024 | $1.3B | +7.8% |
| FY2023 | $1.2B | +1.3% |
| FY2022 | $1.2B | -16.9% |
| FY2021 | $1.4B | -5.4% |
| FY2020 | $1.5B | +43.0% |
| FY2019 | $1.1B | +5.0% |
| FY2018 | $1.0B | +9.5% |
| FY2017 | $924.0M | -0.2% |
| FY2016 | $926.0M | +2.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026